Alvotech (ALVO) Liabilities and Shareholders Equity (2020 - 2026)
Alvotech (ALVO) posted Liabilities and Shareholders Equity of $1.4 billion for Q1 2026, down 4.43% on a QoQ basis from $1.5 billion in Q4 2025, and up 14.11% year-over-year from $1.2 billion in Q1 2025.
Alvotech (ALVO) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Alvotech's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 14.11% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 19.75% YoY) and the FY2025 annual result came in at $1.5 billion, up 21.75% from the prior year.
- Liabilities and Shareholders Equity was $1.4 billion for Q1 2026 at Alvotech, down from $1.5 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2025 and bottomed at $774.5 million in Q2 2022.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 38.54% — and 2026, when it climbed 14.11%.
- Alvotech's Liabilities and Shareholders Equity stood at $828.4 million in 2022, then grew by 14.68% to $950.1 million in 2023, then gained by 28.56% to $1.2 billion in 2024, then gained by 21.75% to $1.5 billion in 2025, then dropped by 4.43% to $1.4 billion in 2026.
- Business Quant data shows ALVO's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 1.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.42 Bn |
| Dec 31, 2025 | 1.49 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 1.25 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.07 Bn |
| Mar 31, 2024 | 1.06 Bn |
| Dec 31, 2023 | 950.09 Mn |
| Jun 30, 2023 | 910.66 Mn |
| Mar 31, 2023 | 895.47 Mn |
| Dec 31, 2022 | 828.44 Mn |
| Jun 30, 2022 | 774.50 Mn |
| Dec 31, 2021 | 597.98 Mn |
| Dec 31, 2020 | 474.42 Mn |